Post-earnings recap
Reported
Mon, Apr 30, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Neurocrine Biosciences reported a significant miss on EPS, which contributed to a slight decline in stock price by 0.73%. The lack of revenue details and guidance may raise concerns among investors about the company's short-term performance. Overall, the results indicate challenges that the company needs to address moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.47 | N/A | -97.56% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the difficulties faced this quarter. They emphasized their commitment to long-term objectives without providing specific guidance.
Management did not provide specific details on revenue performance.
The company is focusing on long-term growth despite current challenges.